Bone Abstracts

Osteosarcoma is the most common primary malignant bone tumor, characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments points out the importance of exploring new therapeutic ways. Imatinib Mesylate (Glivec, Novartis Pharma), a tyrosine kinase inhibitor, has been originally developed for the treatment of chronic myeloid leukemia. Several studies revealed that Imatinib Mesylate inhibits osteoclast differentiation th...

Background: High doses of zoledronic acid (ZOL), one of the most potent inhibitors of bone resorption; is currently evaluated in a phase III clinical trial in Europe for the treatment of malignant pediatric primary bone tumors. The impact of such an intensive treatment on the craniofacial skeleton is a critical question in the context of patients with actively growing skeleton; in particular in the light of our previous studies evidencing that endochondral bone formation was t...

Interleukin-34 (IL-34) is a newly discovered cytokine which regulates, like macrophage-colony stimulating factor (M-CSF), the differentiation/activation of the myeloid lineage. IL-34 and M-CSF are homodimers known to bind to the M-CSF receptor (M-CSFR) in a competitive manner. In this system, IL-34 can substitute for the M-CSF to induce osteoclastic differentiation. The aim of the present work was to study the functional relationships of these cytokines on cells expressing the...

Interleukin- 34 (IL34) is a new, challenging cytokine discovered in 2008. It promotes the proliferation, survival and differentiation of the monocyte/macrophage lineage with almost the same efficiency as the macrophage-colony stimulating factor (M-CSF). IL34 has already been described to play a key role in various musculoskeletal bone diseases such as bone giant cell tumors or in rheumatoid arthritis. These ‘twin’ cytokines share a lot of functional similarities whic...

Osteosarcoma, the main malignant primary bone tumor, affects a ‘young’ population composed of children and young adults. Current treatment consists of tumor resection associated with chemotherapy. Unfortunately in many cases, a lack of response to anti-tumor drugs is observed, leading to development of metastases and to the patient’s death. Because TGF-β promotes metastases from many solid epithelial tumors, we investigated the effect of inhibitory Smad7 ov...

Tumour growth and metastatic dissemination are significantly reduced in mice bearing an inactivation of the macrophage-colony stimulating factor (M-CSF) gene, due to angiogenesis impairment. In fact, M-CSF directly induces angiogenesis by increasing vascular endothelial growth factor (VEGF) production. Interleukin 34 (IL34), the M-CSF’s ‘twin’ cytokine, was characterized as a new cytokine promoting the growth, survival and differentiation of the myeloid lineage....

Background: High zoledronic acid (ZOL) dose protocol, one of the most potent inhibitors of bone resorption, is currently evaluated in a phase III clinical trial in Europe for the treatment of malignant pediatric primary bone tumors. The impact of such an intensive treatment on the craniofacial skeleton growth is a critical question in the context of patients with actively growing skeleton, in the light of our previous studies evidencing that endochondral bone formation was tra...